SCHEMBL6208878

SCHEMBL6208878

O=C(O)C1(S(=O)(=O)c2ccc(-c3ccc(CCC(F)(F)C(F)(F)F)cc3)nc2)CCOCC1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 13/20 0.40
MMP9 P14780 13/20 0.40
MMP3 P08254 12/20 0.40
MMP13 P45452 12/20 0.40
MMP8 P22894 11/20 0.40
MMP7 P09237 2/20 0.40
PHGDH O43175 1/20 0.40
DGAT1 O75907 1/20 0.40
GCK P35557 1/20 0.39
GCKR Q14397 1/20 0.39
MMP14 P50281 5/20 0.39
MMP10 P09238 1/20 0.39
MMP12 P39900 1/20 0.39
MMP1 P03956 7/20 0.38
ADAM17 P78536 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5908780 0.94 MMP2 (0.42) MMP2MMP9MMP3MMP13MMP8
SCHEMBL6231419 0.93 MMP2 (0.41) MMP2MMP9MMP3MMP13MMP8
Hydrochloric Acid SCHEMBL6208482 0.92 MMP2 (0.48) MMP2MMP9MMP3MMP13MMP8
SCHEMBL8313315 0.90 MMP2 (0.40) MMP2MMP9MMP3MMP13MMP8
SCHEMBL6206525 0.89 MMP13 (0.38) MMP2MMP9MMP3MMP13MMP8
SCHEMBL5908649 0.89 MMP13 (0.47) MMP2MMP9MMP3MMP13MMP8
SCHEMBL5908727 0.86 PHGDH (0.42) MMP2MMP9MMP3MMP13MMP8
Hydrochloric Acid SCHEMBL5908638 0.86 MMP2 (0.50) MMP2MMP9MMP3MMP13MMP8
SCHEMBL8316685 0.85 MMP2 (0.50) MMP2MMP9MMP3MMP13MMP8
Trifluoroacetic Acid SCHEMBL6205958 0.84 RAB9A (0.46) MMP2MMP9MMP3MMP13MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1565459-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS Pharmacia Corporation (US) 2005-08-24 EP disclosed
US-20040142979-A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors PHARMACIA CORPORATION 2004-07-22 US disclosed
WO-2004048368-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2004-06-10 WO disclosed
WO-2004048368-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142979-A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors MMP3, MMP13, MMP10 MMP2 6/4885MMP9 7/4885MMP3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.